Taken together, these findings indicate that SLX4IP and TMM identity are strongly associated with disease progression and therapeutic response to ATR inhibitors and 5-FdU; they also suggest that elucidating breast cancer TMM status may provide new insights to inform treatment selection. This evidence concerns the gene SLX4IP and breast cancer.